FDA's Top Q4 Blockbuster Drug Decisions

FDA's Top Q4 Blockbuster Drug Decisions

Submitted by admin on October 12, 2010 - 11:26am
Source: 
Fierce Biotech
News Tags: 
Linjeta
Biodel
Afrezza
MannKind
FDA
Benlysta
Human Genome
GSK
Bydureon
Eli Lilly
Amylin
Alkermes
Brilinta
AstraZeneca
Pradaxa
Boehringer Ingelheim
Qnexa
Vivus
Contrave
Orexigen
ipilimumab
Bristol-Myers Squibb
Merck KGaA
cladribine
Headline: 
FDA's Top Q4 Blockbuster Drug Decisions

Do Not Allow Advertisers to Use My Personal information